Linked Life Data

3311238

Source:http://linkedlifedata.com/resource/pubmed/id/3311238

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1987-12-11
pubmed:abstractText
Twenty-two oophorectomized or postmenopausal women with metastatic breast cancer resistant to several medical therapies (tamoxifen, or other endocrine therapy, and chemotherapy) were treated in a first trial with 200 mg per day of RU486 for 1 to 3 months. The long-term tolerance was good but there was a moderate decrease in plasma potassium. Plasma cortisol was increased 2-fold without clinical hypo- or hypercorticism. Twelve patients had a partial response or a stabilization of secondary deposits for 6 weeks but the response rate at 3 months was 18%. When available, estrogen and progesterone receptor levels were positive in these patients. This preliminary trial shows for the first time that the antiprogestin RU486 is well tolerated for medium term treatment. It suggests that it might be active on advanced breast cancer becoming resistant to tamoxifen.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0007-4551
pubmed:author
pubmed:issnType
Print
pubmed:volume
74
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
455-61
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial.
pubmed:affiliation
Centre Paul-Lamarque, Hôpital Saint-Eloi, Montpellier, France.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't